Trials / Completed
CompletedNCT03455439
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 552 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with rivaroxaban.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | As prescribed by the treating physician |
Timeline
- Start date
- 2018-03-16
- Primary completion
- 2021-07-17
- Completion
- 2022-01-11
- First posted
- 2018-03-06
- Last updated
- 2023-11-07
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03455439. Inclusion in this directory is not an endorsement.